Rick and athers:
Anyone who can put hand on this manuscript or at least abstract?
>>Adv Pharmacol 1998;42:915-921
Cell body infusions of brain-derived neurotrophic factor increase forebrain dopamine release and serotonin metabolism determined with in vivo microdialysis.
Altar CA, Fritsche M, Lindsay RM
Regeneron Pharmaceuticals, Inc., Tarrytown, New York 10591, USA.
PMID: 9328047, UI: 97468982<<
Also, this abstract may add few *candles* on BDNF ambiguity:
Nature 1997 Oct 23;389(6653):856-860
Anterograde transport of brain-derived neurotrophic factor and its rol in the brain.
Altar CA, Cai N, Bliven T, Juhasz M, Conner JM, Acheson AL, Lindsay RM, Wiegand SJ
Regeneron Pharmaceuticals, Inc., Tarrytown, New York 10591, USA.
The role of neurotrophins as target-derived proteins that promote neuron survival following their retrograde transport from the
terminals to the cell bodies of neurons has been firmly established in the developing peripheral nervous system. However,
neurotrophins appear to have more diverse functions, particularly in the adult central nervous system. Brain-derived
neurotrophic factor (BDNF), for example, produces a variety of neuromodulatory effects in the brain that are more consistent
with local actions than with long-distance retrograde signalling. Here we show that BDNF is widely distributed in nerve
terminals, even in brain areas such as the striatum that lack BDNF messenger RNA, and that inhibition of axonal transport or
deafferentation depletes BDNF. The number of striatal neurons that contain the calcium-binding protein parvalbumin was
decreased in BDNF+/- and BDNF-/- mice in direct proportion to the loss of BDNF protein, which is consistent with
anterogradely supplied BDNF having a functional role in development or maintenance. Thus the anterograde transport of
BDNF from neuron cell bodies to their terminals may be important for the trafficking of BDNF in the brain.<<
mz |
